Ascendis Pharma to regain TransCon rights in metabolic diseases
Ascendis Pharma has confirmed it will regain exclusive rights to develop, manufacture, and commercialise TransCon technology-based products across metabolic and cardiovascular diseases, following the termination of its collaboration agreement with Novo Nordisk. The reversion, which stems from a termination first announced in November 2024, leaves neither party with continuing financial obligations to the other.
The Copenhagen-headquartered biopharmaceutical company said it plans to initiate multiple programmes in both rare and large metabolic and cardiovascular indications. The lead asset in that expanded effort will be once-monthly TransCon Semaglutide, an investigational long-acting prodrug of the GLP-1 receptor agonist semaglutide, being developed as a potential treatment for obesity and type 2 diabetes.
The deal in context
The partnership with Novo Nordisk, struck before semaglutide's explosive commercial trajectory under the Ozempic and Wegovy brands, was clearly valued by both sides as a way to extend reach in the GLP-1 space. Its unravelling leaves Ascendis in the unusual position of independently advancing a long-acting semaglutide formulation in direct competition with the world's dominant diabetes and obesity franchise. The company has not disclosed the precise grounds for termination, and the forward-looking statement in its release flags a residual risk of disputes over breach claims.
President and chief executive Jan Mikkelsen framed the reversion as consistent with the company's Vision 2030 strategy. "Our algorithm for product innovation has delivered three consecutive approved products," he said, "and we are excited to apply our versatile TransCon platform with the same disciplined approach across these therapeutic areas." Ascendis has won regulatory approvals for TransCon-based products in growth hormone deficiency and hypoparathyroidism, lending some credibility to the platform's track record in rare endocrine disease. Translating that to large-population cardiometabolic indications is a substantially more capital-intensive undertaking.
Market landscape
The GLP-1 receptor agonist market is among the most contested in biopharma. Novo Nordisk and Eli Lilly together dominate with semaglutide and tirzepatide, while a broad field of challengers is pursuing differentiated formulations, oral delivery, and longer dosing intervals. Once-monthly injectable regimens represent one of the more credible near-term competitive angles, as both patients and healthcare systems look for alternatives to weekly injections. Ascendis's TransCon prodrug technology, which uses controlled-release conjugation chemistry to extend half-life, is positioned by the company as capable of delivering that dosing profile.
Whether an independently funded Ascendis can advance TransCon Semaglutide at the pace required to matter in a market that is consolidating rapidly around proven brands is the central question facing investors. The company has not disclosed a clinical timeline, a development budget, or whether it intends to seek a new partnership to share the cost and risk. Those details, along with any regulatory feedback on a potential IND or CTA filing, will be the near-term milestones to watch. Ascendis's share price and cash position at the time of effective reversion will also shape how much flexibility it retains to execute the broader Vision 2030 cardiometabolic agenda.